Affiliation:
1. A.N. Bakulev Scientific Center for Cardiovascular Surgery of the Ministry of Health of the Russian Federation
2. R.M. Gorbacheva Research Institute of Pediatric Oncology, Hematology and Transplantation
Abstract
Purpose: To analyse the prognostic value of the initial volumetric PET biomarkers – the total metabolic tumor volume (MTV) and the total lesion glycolysis (TLG) – in classic Hodgkin's lymphoma (cHL) and determine their optimal threshold values for prognosis.Material and methods. This retrospective study included 62 cHL patients with different stages who underwent staging with 18F-FGD PET/CT. The follow-up period was from 6 to 61 months after the baseline PET/CT, 41 patients remained in remission, 10 patients had refractory course, 11 relapsed. The examinations were processed with automatic (multi-foci segmentation – MFS) method to obtain MTV and TLG using two fixed absolute thresholds (SUVmax ≥ 2.5 and SUVmax ≥ 4.0) and one relative threshold (41% of SUVmax).Results. In subgroups with disease remission (n = 41) and refractory course or relapse (n = 21), statistically significant differences between MTV and TLG with the two thresholds were found – SUVmax ≥ 2.5 and 41% of SUVmax (p < 0.05). When using threshold of SUVmax ≥ 4.0 statistically differences between the mean of MTV and TLG were no detected.Univariate analysis revealed correlation between progression-free survival and volumetric PET biomarkers (MTV and TLG) with three thresholds (SUVmax ≥ 2.5, SUVmax ≥ 4.0, and 41% of SUVmax).Conclusion. In cHL high values of initial volumetric PET biomarkers – MTV and TLG – calculated with three thresholds (SUVmax ≥ 2.5, SUVmax ≥ 4.0, and 41% of SUVmax) are associated with unfavourable prognosis – a high probability of refractory disease course or relapse.The optimal prognostic thresholds values of MTV and TLG in the analysed group were determined respectively: SUVmax ≥ 2.5 – 204 cm3 and 961, at 41% of SUVmax – 105 cm3 and 620.
Subject
Radiology, Nuclear Medicine and imaging,Radiological and Ultrasound Technology
Reference27 articles.
1. Howlader N., Noone A.M., Krapcho M. et al. SEER Cancer Statistics Review. 1975–2016. https://seer.cancer.gov/csr/1975_2016/. Accessed April 9, 2020.
2. Kobe C., Dietlein M., Franklin J. et al. Positron emission tomography has a high negative predictive value for progression or early relapse for patients with residual disease after first-line chemotherapy in advanced stage Hodgkin lymphoma. Blood. 2008; 112: 3989–3994. https://doi.org/10.1182/blood-2008-06-155820
3. Weihrauch M.R., Re D., Bischoff S. et al. Whole-body positron emission tomography using 18F-fluorodeoxyglucose for initial staging of patients with Hodgkin's disease. Ann. Hematol. 2002; 81: 20–5. https://doi.org/10.1007/s00277-001-0390-y
4. Gallamini A., Rigacci L., Merli F. et al. The predictive value of positron emission tomography scanning performed after two courses of standard therapy on treatment outcome in advanced stage Hodgkin's disease. Haematologica. 2006; 91: 475–481. PMID: 16585014
5. Gallamini A., Hutchings M., Rigacci L. et al. Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: a report from a joint Italian-Danish study. J. Clin. Oncol. 2007; 25: 3746–3752. https://doi.org/10.1200/jco.2007.11.6525